A Multi-Reader Multi-Case Controlled Clinical Trial to Evaluate the Comparative Accuracy Of Readers Assisted By an AI/ML Technology-Based End-To-End CADe/CADx SaMD Versus Alone in the Detection, Localization and Characterization of Pulmonary Nodules in Populations With High Risk of Lung Cancer (RELIVE)
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 480
- 试验地点
- 5
- 主要终点
- ∆ AUC of ROCs > 0. Delta Area between the Response operating curve (AUROC) value with Median LCS and AUROC without Median LCS at patient level data is superior to 0.
研究概览
简要总结
This is a two arm, randomized, controlled, blinded, multi-case multi reader (MRMC), retrospective study for the evaluation of the efficacy and safety of an AI/ML technology-based CADe/x developed to detect, localize and characterize malignancy score of pulmonary nodules on LDCT chest scans taken as part of a lung cancer screening program.
LDCT DICOM images of patients who underwent routine lung cancer screening will be selected and enrolled into the study. Enrolled scans analyzed by radiologists with the assistance of the Median LCS (formerly iBiopsy) device are compared to the analysis by radiologists without the assistance of the Median LCS device.
Figures of merit for patient level and lesion level detection and diagnostic efficacy will be calculated and compared, sub-class analysis will be performed to ensure device generalizability.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 50 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •≥50-80 Years of age;
- •Current or ex-smoker (>=20 pack years);
- •Patient screened and surveilled for lung cancer screening following lung cancer screening guidelines (equivalent to United States Preventive Services Task Force (USPSTF) 2021 Criteria);
- •Received LDCT due to inclusion in high-risk category for lung cancer.
排除标准
- •Prior lung resection;
- •Pacemaker or other indwelling metallic medical devices in the thorax that interfere with CT acquisition;
- •Patients/images used during AI model development;
- •Patients with only hilar and/or mediastinal cancer(s);
- •Patients with only ground glass cancer(s);
- •Patients with nodules, solid or part-solid >30mm (masses);
- •Patients that are not accompanied with the required clinical information;
- •Patients with imaging with any of the following: missing slices, slice thickness >3mm;
- •Partial cover of the lung.
结局指标
主要结局
∆ AUC of ROCs > 0. Delta Area between the Response operating curve (AUROC) value with Median LCS and AUROC without Median LCS at patient level data is superior to 0.
时间窗: 12 months
Demonstrate that patient diagnosis with Median LCS is improved compared to without Median LCS.
次要结局
- Sensitivity at max Youden(12 months)
- Specificity at max Youden(12 months)
- ∆ AUC of LROC > 0(12 months)
- Recall rates for non-cancer patients (Specificity)(12 months)
- Recall rates for cancer patients (Sensitivity)(12 months)
- Time analysis(12 months)